Pharmaceutical Technology

SEPTEMBER 8, 2022

Biologics development is a complex and expensive process. The list includes providers of development services, biologics management supply chain solutions, clinical trial services, commercial and logistics services, as well as packaging, labelling and distributing services for biologics.

Gene 100

Gene Marketing Vaccine Vaccination 100

The Pharma Data

SEPTEMBER 11, 2021

Boehringer Ingelheim believes Twist’s ability to generate potent, diverse therapeutic antibodies by mining its comprehensive libraries, combined with our extensive capabilities and experience in drug discovery and development, will enable us to deliver breakthrough opportunities to patients,” said Clive R.

Antibody 52

Antibody DNA Containment Manufacturing 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Vaccine 130

Vaccine Vaccination Containment Immune Response 130

The Pharma Data

NOVEMBER 25, 2020

26, 2020 /PRNewswire/ — Cantargia AB (OMXS: CANTA) and BioInvent International AB (OMXS: BINV), today announced that BioInvent has been contracted as manufacturer of Cantargia’s antibody CAN10 in preclinical development for the treatment of systemic sclerosis and myocarditis. LUND, Sweden , Nov. About BioInvent.

Antibody 52

Antibody Manufacturing Clinical Trials Clinical Trials 52

Worldwide Clinical Trials

SEPTEMBER 29, 2022

For studies of humanized therapeutics (monoclonal antibodies [mAb], fusion protein, antibody-drug conjugates [ADC], bispecific antibodies, etc.), If so, it’s important to plan for development of this assay as within the project timeline. anti-human IgG).

Reagent 130

Reagent Clinical Trials Clinical Trials Antibody 130

The Pharma Data

SEPTEMBER 17, 2020

17, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly ‘s potential COVID-19 therapies. executive vice president of research and development at Amgen. Reese , M.D.,

Antibody 52

Antibody Manufacturing Production Sales 52

pharmaphorum

NOVEMBER 2, 2021

Dr Laura Moriarty, senior marketing manager at Bio-Rad, looks at the impressive immuno-therapeutic potential of bispecific antibodies (bsAbs). Though their bispecific nature complicates large-scale production and purification workflows, with challenges such as antibody chain mispairing, bsAbs have come a long way since first developed.

Antibody 52

Antibody Immune Response Production Engineer 52

The Pharma Data

DECEMBER 20, 2020

PARTNERSHIP LEVERAGES COMPLEMENTARY STRENGTHS OF IN SILICO, IN VITRO AND IN VIVO ANTIBODY DISCOVERY IN A RANGE OF INDICATIONS. EVOTEC GAINS ACCESS TO ALLOY THERAPEUTICS’ ATX-GX(TM) HUMANISED MICE PLATFORM FOR BIOLOGICS DISCOVERY.

Antibody 52

Antibody In-Vivo In-Vitro Scientist 52

The Pharma Data

DECEMBER 11, 2020

The test has been designed to quantitatively measure of immunoglobulin G (IgG) antibodies to aid clinicians in identifying patients with an immune Covid-19 response pre- and post-vaccination. As we follow individuals over the course of a year, we are repeatedly testing them for both virus and antibodies.”.

Antibody 52

Antibody Vaccine Vaccination Containment 52

Roots Analysis

DECEMBER 11, 2022

Antibody drug conjugates (ADCs) are an upcoming class of targeted therapeutic agents that have garnered the attention of pharmaceutical companies, and academic / research institutions across the world. Antibody drug conjugates market is presently an established therapeutic concept with 11 approved products.

Antibody 40

Antibody Marketing Contract Manufacturing Drugs 40

The Pharma Data

DECEMBER 12, 2020

Chief Executive Officer, Alexion , said: “For nearly 30 years Alexion has worked to develop and deliver transformative medicines to patients around the world with rare and devastating diseases. More recently, AstraZeneca has increased its efforts in immunology research and the development of medicines for immune-mediated diseases.

Development 75

Development Regulation Medicine Containment 75

pharmaphorum

OCTOBER 2, 2020

European regulators have started a first ‘rolling review’ of a COVID-19 vaccine, which is being developed by AstraZeneca in collaboration with the University of Oxford. In a separate announcement, AstraZeneca said that a trial of the vaccine has resumed in Japan after a safety scare in the UK.

Regulation 105

Regulation Vaccine Vaccination Protein 105

pharmaphorum

NOVEMBER 28, 2021

billion takeover of Sativex’ developer GW Pharma earlier this year. The drug is – an oral spray containing cannabinoids THC and CBD which is already licensed and sold by other companies in some markets for neuropathic pain, spasticity, overactive bladder, and other symptoms of multiple sclerosis.

Trials 136

Trials Drugs Clinical Trials Clinical Trials 136

Delveinsight

OCTOBER 1, 2021

This disease is associated with antibodies directed against the acetylcholine receptor, muscle-specific kinase (MUSK), lipoprotein-related protein 4 (LRP4), or agrin in the postsynaptic membrane at the neuromuscular junction. Prograf is available for oral administration in the form of capsules (tacrolimus capsules USP) containing 0.5

Marketing 85

Marketing Antibody Drugs Sales 85

The Pharma Data

OCTOBER 25, 2020

Company Confirms COVID-19 Antibody Home Test and Two Severity Triage Tests can be Submitted to U.S. SQI is accelerating the clinical development of its direct-to-consumer COVID-19 HOME Antibody Test, its COVID-19 RALI-dx Severity Triage Test and its COVID-19 RALI- fast Severity Triage Point-of-Care (POC) Test.

Development 52

Development Antibody Clinical Development FDA Approval 52

Pharmaceutical Technology

AUGUST 24, 2022

The global immunotherapy market, which includes CAR T-cell therapy, adoptive cell therapies, checkpoint inhibitors, monoclonal antibodies, and other immunotherapies, is expected to grow by 10.1% Patients provide blood samples for clinical trial sponsors to develop and deliver these emerging immunotherapies. CAGR between 2020 and 2028.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Development 130

The Pharma Data

NOVEMBER 30, 2020

Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. GAITHERSBURG, Md., and Australia.

Clinical Development 52

Clinical Development Vaccine Vaccination Development 52

XTalks

DECEMBER 14, 2021

Moderna designed its mRNA influenza vaccine in January of this year and began human testing just five months ago, highlighting the speed at which mRNA vaccines can be developed. The vaccine successfully boosted HA antibody titers against all strains 29 days after vaccination with all of the doses evaluated in both young and older adults.

Vaccine 98

Vaccine Vaccination Immune Response Antibody 98

The Pharma Data

DECEMBER 17, 2020

NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , 17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Medicine Production Trials 52

The Pharma Data

DECEMBER 23, 2020

Agreement leverages Aurobindo’s existing development, commercial and manufacturing infrastructure. Commenting on the development, Mr. N. This vaccine has immense potential in eliminating shedding, and hence containing, the spread of the pandemic.” . HYDERABAD, India , Dec.

Vaccine 52

Vaccine Vaccination Development Manufacturing 52

pharmaphorum

AUGUST 16, 2020

The European Commission has placed its first advance order for a coronavirus vaccine, snapping up 300 million doses of AstraZeneca’s ChAdOx1 candidate developed by the University of Oxford, with an option on another 100 million. The EU says its advance purchase order will finance part of the upfront costs of developing the vaccine.

Vaccine 111

Vaccine Vaccination Immune Response Trials 111

The Pharma Data

JANUARY 4, 2021

IPH6101/SAR443579 is an NKp46-based NK cell engager (NKCE) that uses Innate’s proprietary multispecific antibody format. IPH6101/SAR443579 is a NKp46-based NK cell engager (NKCE) using Innate’s proprietary multispecific antibody format (Gauthier et al. MARSEILLE, France, Jan. MARSEILLE, France, Jan. Cell 2019 ).

Development 40

Development Antibody Drugs Containment 40

Pharmaceutical Technology

APRIL 16, 2023

But with the advent of injection site absorption enhancers, drug delivery device innovations, as well as the recent primary container options, the practical subcutaneous self-administration of large-volume parenterals is becoming possible. mL or less and use a prefilled syringe (PFS) with a staked needle as the drug’s primary container.

Protein 130

Protein Containment Drug Delivery Drugs 130

pharmaphorum

DECEMBER 4, 2020

Johnson & Johnson has filed its bispecific antibody amivantamab to the FDA, hoping to muscle into the big market for drugs that are used to treat EGFR-positive non-small cell lung cancer (NSCLC). The Exon 20-mutated population is fairly large in its own right, as these mutations are the third most prevalent primary EGFR mutation.

FDA Approval 93

FDA Approval Sales Antibody Drugs 93

The Pharma Data

AUGUST 15, 2021

Even as several safe and effective COVID-19 vaccines are being administered to people worldwide, scientists are still hard at work developing different vaccine strategies that could provide even stronger or longer-lasting immunity against SARS-CoV-2 and its variants.

Protein 52

Protein Vaccine Vaccination Antibody 52

The Pharma Data

JANUARY 12, 2021

Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g. NEW YORK and LONDON, Jan. Graham earned an M.D.,

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

XTalks

MARCH 29, 2021

Grantz, of the Division of Intramural Population Health Research at NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development. Related: Maternal Antibodies: How Allergies Can be Passed from Mothers to Children. Katherine L.

Genotype 98

Genotype Allergies Hormones Research 98

XTalks

JANUARY 9, 2024

Related: Glaucoma Awareness Month 2024: New and Promising Treatments for Glaucoma Thyroid Disease Statistics According to the American Thyroid Association (ATA), more than 12 percent of Americans will develop a thyroid condition in their lifetime. Blocking FcRn-IgG interactions : RVT-1401, rozanolixizumab and efgartigimod in a Phase II trial.

Hormones 105

Hormones Antibody Trials Production 105

pharmaphorum

OCTOBER 31, 2022

s Inmazeb (consisting of the monoclonal antibodies atoltivimab, maftivimab, and odesivimab-ebgn). Indeed, Regeneron believes that the success with Ebola could potentially have ushered in “a new era in which monoclonal antibodies could be used to fight viral diseases and global pandemics.”.

Production 52

Production FDA Approval Antibody Gene 52

The Pharma Data

JANUARY 10, 2021

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / January 11, 2021 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, announced today that Jean-Paul Kress, M.D., In July 2020, the U.S.

Containment 52

Containment Clinical Development Antibody Development 52

The Pharma Data

OCTOBER 28, 2020

NASDAQ: REGN) today announced positive, prospective results from an ongoing Phase 2/3 seamless trial in the COVID-19 outpatient setting showing its investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints. Senior Vice President and Head of Global Clinical Development at Regeneron. Yancopoulos , M.D.,

Antibody 40

Antibody Trials Production Clinical Trials 40

The Pharma Data

JANUARY 27, 2021

RIIB antibody BI-1206 in combination with rituximab (anti-CD20 monoclonal antibody) in patients with indolent relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). ET ) to discuss the results and next steps in clinical development of BI-1206. (Nasdaq: CASI), a U.S. Nasdaq: CASI), a U.S.

Antibody 52

Antibody Containment Development Trials 52

The Pharma Data

JUNE 25, 2021

protofibril antibody for the treatment of Alzheimer’s disease (AD). Breakthrough Therapy designation is an FDA program intended to expedite the development and review of medicines for serious or life-threatening conditions. You should not place undue reliance on these statements or the scientific data presented.

Antibody 40

Antibody Clinical Trials Clinical Trials Development 40

The Pharma Data

NOVEMBER 9, 2020

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Currently in late-phase clinical development, NVXCoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes its proprietary MatrixM adjuvant. “The

Vaccine 52

Vaccine Vaccination Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 5, 2020

NASDAQ: REGN) today announced updated data for REGN5458, a BCMAxCD3 bispecific antibody, from the Phase 1 portion of a Phase 1/2 trial in patients with relapsed or refractory (R/R) multiple myeloma. These allow for the creation of bispecific antibodies that closely resemble natural human antibodies with no linkers or artificial sequences.

Antibody 40

Antibody Production Trials Medicine 40

The Pharma Data

DECEMBER 1, 2020

is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. About Innate Pharma: Innate Pharma S.A. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia.

Containment 52

Containment Antibody Production Engineer 52

Roots Analysis

FEBRUARY 15, 2022

Over time, medical researchers have been able to further develop their understanding of the intricacies of ADC design and have also improved the development process of these complex pharmacological interventions. ADC Cytotoxic Payloads / Warheads Developers. Want additional details on the ADC Payloads / Warheads Developers?

Contract Manufacturing 52

Contract Manufacturing Manufacturing Marketing Containment 52